Pfizer's Prevnar 13 Could Gain Edge With Vaccine Panel Review
Executive Summary
An endorsement from FDA's Vaccines and Related Biological Products Advisory Committee for Wyeth's (now Pfizer's) Prevnar 13 would be a positive step for the firm in its race against GlaxoSmithKline rival vaccine Synflorix to capture the next-generation pneumococcal vaccine market
You may also be interested in...
Prevnar 13 Faces Two Disparate Challenges At Advisory Committee
Next-generation pneumococcal vaccine failed to show non-inferiority on several serotypes, and there is little scientific consensus about the criteria for its second proposed indication, otitis media.
Prevnar 13 Faces Two Disparate Challenges At Advisory Committee
Next-generation pneumococcal vaccine failed to show non-inferiority on several serotypes, and there is little scientific consensus about the criteria for its second proposed indication, otitis media.
Growing Up: Vaccine Market Increasingly Targets Adults
This past spring, the executive team at 1Intercell AG received the proverbial shot in the arm. After a decade of research and testing, their Ixiaro vaccine for combating Japanese encephalitis was approved by the FDA and then recommended by the Advisory Committee on Immunization Practices